Fund Tracker India by Ishaan Dungarwal
Guide

Nippon India Pharma Fund

Holdings for Oct 2026, changes against Sep 2026, from Nippon India Mutual Fund's monthly file.

Nippon India Pharma Fund portfolio holdings, Oct 2026: 37 stocks, ₹9,051 cr in listed equity, from Nippon India Mutual Fund's monthly disclosure; changes by share count against Sep 2026.

Fund managers: Sailesh Raj Bhan

Benchmark: BSE Healthcare TRI · Riskometer: Very High · SEBI category, as filed: Sectoral Fund · Allotted 5 Jun 2004

Source: AMFI scheme summary document

NAV

Nippon India Pharma Fund - Direct Plan - Growth Option

Source: AMFI

₹659.361316 Nov 2026
AUM

average for July - September 2026, all plans.

Source: AMFI

₹9,272 crJuly - September 2026
Expense ratio

The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.

Category median: direct 1.07 %, regular 2.50 % (20 schemes) · Regular costs ₹860 more a year per ₹1 lakh

Of this, the base expense ratio, the part SEBI caps: direct 0.78 %, regular 1.51 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.

A year, as of 16 Nov 2026. Source: AMFI · Glossary: TER

Direct 0.98 %Regular 1.84 %
Equity held

37 stocks, Oct 2026.

Source: Nippon India Mutual Fund monthly portfolio

₹9,051 cr37 stocks · Oct 2026
Equity, % of fund

As the AMC's file prints % of NAV. The top 10 stocks together: 57.2%.

99.6%top 10 stocks 57.2%

This month: Oct 2026

compared with Sep 2026 · by share count

Equity held vs NAV

The teal line is the scheme's equity at month end, from its portfolio file; the faint line is the plan's NAV. Equity held moves with prices and with money in or out, the NAV with prices only.

last 12 months to Oct 2026
Nov 2025: equity held ₹8,412 cr, 36 stocks, NAV ₹581.12Dec 2025: equity held ₹8,047 cr, 36 stocks, NAV ₹569.82Jan 2026: equity held ₹7,794 cr, 35 stocks, NAV ₹545.50Feb 2026: equity held ₹8,281 cr, 35 stocks, NAV ₹576.92Mar 2026: equity held ₹7,856 cr, 35 stocks, NAV ₹548.92Apr 2026: equity held ₹8,255 cr, 34 stocks, NAV ₹579.98May 2026: equity held ₹8,456 cr, 34 stocks, NAV ₹598.50Jun 2026: equity held ₹8,828 cr, 35 stocks, NAV ₹626.14Jul 2026: equity held ₹9,030 cr, 35 stocks, NAV ₹640.39Aug 2026: equity held ₹9,289 cr, 36 stocks, NAV ₹653.61Sep 2026: equity held ₹8,919 cr, 36 stocks, NAV ₹630.22Oct 2026: equity held ₹9,051 cr, 37 stocks, NAV ₹625.46
% change and month by month (tables)
% change to Oct 2026
OverSinceEquity heldNAV
3 monthsJul 2026▲ +0.2%▼ −2.3%
6 monthsApr 2026▲ +9.6%▲ +7.8%
12 monthsOct 2025▲ +8.8%▲ +9.4%
MonthEquity heldStocksNAV at month end
Nov 2025₹8,412 cr36₹581.1187
Dec 2025₹8,047 cr36₹569.8166
Jan 2026₹7,794 cr35₹545.5001
Feb 2026₹8,281 cr35₹576.9248
Mar 2026₹7,856 cr35₹548.9228
Apr 2026₹8,255 cr34₹579.9839
May 2026₹8,456 cr34₹598.5008
Jun 2026₹8,828 cr35₹626.1360
Jul 2026₹9,030 cr35₹640.3925
Aug 2026₹9,289 cr36₹653.6135
Sep 2026₹8,919 cr36₹630.2169
Oct 2026₹9,051 cr37₹625.4566
Oct 2026 · Sources: AMC monthly portfolio (SEBI disclosure); AMFI NAV files · How to read

Moves, Oct 2026

How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.

vs Sep 2026
  • New1
  • Added5
  • Trimmed3
  • Exited0
Stocks, by share count · Source: Nippon India Mutual Fund monthly portfolios Report a wrong number

Asset mix, Oct 2026

How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.

% of fund
  1. Listed equity
    99.6%
  2. Rest, not itemised
    0.4%
Source: Nippon India Mutual Fund monthly portfolio

Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.

Sectors and top 10, Oct 2026

Sector mix, Oct 2026

How the scheme's equity is spread across sectors at month end.

% of equity held
Source: Nippon India Mutual Fund monthly portfolio; AMFI

AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.

Report a wrong number

Large, mid and small cap, Oct 2026

How the scheme's equity splits across large, mid and small companies, on AMFI's list.

% of equity held
  1. Mid Cap
    40.9%
  2. Large Cap
    29.7%
  3. Small Cap
    28.8%
  4. Not in AMFI's list
    0.5%
Source: Nippon India Mutual Fund monthly portfolio; AMFI

AMFI's list of Jun 2026.

Report a wrong number

Top 10 holdings

Its ten largest stocks, each as a share of the fund.

% of fund · 57.2% together
  1. 11.55%
  2. 6.73%
  3. 6.21%
  4. 6.16%
  5. 6.13%
  6. 5.10%
  7. 4.40%
  8. 4.04%
  9. 3.53%
  10. 3.31%
Source: Nippon India Mutual Fund monthly portfolio

As the AMC's file prints % of NAV.

Sector weight change

Each sector's share of the fund now less a month before. It moves with prices as well as trades.

vs Sep 2026 · points of equity held
  1. +0.3 pts
  2. −0.3 pts
Source: Nippon India Mutual Fund monthly portfolios

Largest moves first, up to 10.

Changes, Oct 2026 vs Sep 2026

Every stock whose share count changed: new, added, trimmed, exited.

9 stocks · by share count
StockChangeShares beforeShares nowDifferenceChange %Value of changeValue now
NATCOPHARM New—10.40 lakh+10.40 lakh—+₹81.4 cr₹81.4 cr
DRREDDY Added40.50 lakh41.19 lakh+68,760+1.7%+₹9.3 cr₹557 cr
MAXHEALTH Added26.58 lakh34.98 lakh+8.40 lakh+31.6%+₹72.2 cr₹301 cr
FORTIS Added13.46 lakh26.56 lakh+13.10 lakh+97.3%+₹101 cr₹204 cr
ANTHEM Added12.75 lakh14.20 lakh+1.45 lakh+11.4%+₹12.0 cr₹118 cr
ASTRAZEN Added62,56866,230+3,662+5.9%+₹2.3 cr₹42.2 cr
DIVISLAB Trimmed7.01 lakh6.26 lakh−75,000−10.7%−₹73.3 cr₹612 cr
AUROPHARMA Trimmed9.03 lakh7.67 lakh−1.36 lakh−15.1%−₹22.8 cr₹129 cr
INDOCO Trimmed16.80 lakh16.52 lakh−28,387−1.7%−₹0.59 cr₹34.4 cr
Source: Nippon India Mutual Fund monthly portfolios

Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).

How to read

Report a wrong number

Full portfolio, Oct 2026 (37 stocks)

Every listed stock in the month's file, largest first.

largest first, by value
Company Sector
SUNPHARMASun Pharmaceutical Industries Limited Healthcare59.06 lakh₹1,050 cr11.55%
DIVISLABDivi's Laboratories Limited Healthcare6.26 lakh₹612 cr6.73%
CIPLACipla Limited Healthcare40.95 lakh₹565 cr6.21%
LUPINLupin Limited Healthcare27.84 lakh₹560 cr6.16%
DRREDDYDr. Reddy's Laboratories Limited Healthcare41.19 lakh₹557 cr6.13%
APOLLOHOSPApollo Hospitals Enterprise Limited Healthcare5.49 lakh₹464 cr5.10%
MANKINDMankind Pharma Limited Healthcare16.04 lakh₹400 cr4.40%
SAILIFESai Life Sciences Limited Healthcare23.56 lakh₹367 cr4.04%
AJANTPHARMAjanta Pharma Limited Healthcare9.14 lakh₹321 cr3.53%
MAXHEALTHMax Healthcare Institute Limited Healthcare34.98 lakh₹301 cr3.31%
IPCALABIPCA Laboratories Limited Healthcare13.65 lakh₹263 cr2.90%
GLAXOGlaxosmithkline Pharmaceuticals Ltd. Healthcare10.29 lakh₹257 cr2.83%
GLANDGland Pharma Limited Healthcare8.01 lakh₹248 cr2.73%
VIJAYAVijaya Diagnostic Centre Limited Healthcare16.72 lakh₹242 cr2.66%
PPLPHARMAPiramal Pharma Limited Healthcare99.37 lakh₹237 cr2.61%
MEDPLUSMedPlus Health Services Limited Consumer Services35.45 lakh₹206 cr2.26%
FORTISFortis Healthcare Limited Healthcare26.56 lakh₹204 cr2.25%
ABBOTINDIAAbbott India Limited Healthcare78,546₹201 cr2.22%
LALPATHLABDr. Lal Path Labs Limited Healthcare10.01 lakh₹191 cr2.10%
THYROCAREThyrocare Technologies Limited Healthcare38.38 lakh₹175 cr1.93%
ALKEMAlkem Laboratories Limited Healthcare3.24 lakh₹166 cr1.82%
NHNarayana Hrudayalaya Limited Healthcare8.24 lakh₹142 cr1.56%
SYNGENESyngene International Limited Healthcare35.01 lakh₹141 cr1.55%
AUROPHARMAAurobindo Pharma Limited Healthcare7.67 lakh₹129 cr1.42%
SURAKSHASuraksha Diagnostic Limited Healthcare38.96 lakh₹123 cr1.36%
EMCUREEmcure Pharmaceuticals Limited Healthcare6.41 lakh₹120 cr1.32%
ANTHEMAnthem Biosciences Limited Healthcare14.20 lakh₹118 cr1.30%
PFIZERPfizer Limited Healthcare3.18 lakh₹117 cr1.29%
AKUMSAkums Drugs and Pharmaceuticals Limited Healthcare13.52 lakh₹98.9 cr1.09%
SANOFISanofi India Limited Healthcare3.00 lakh₹96.2 cr1.06%
BIOCONBiocon Limited Healthcare25.04 lakh₹88.1 cr0.97%
NATCOPHARMNatco Pharma Limited Healthcare10.40 lakh₹81.4 cr0.90%
SANOFICONRSanofi Consumer Healthcare India Limited Healthcare2.14 lakh₹73.5 cr0.81%
MOLBIOMolbio Diagnostics Limited Healthcare3.80 lakh₹48.4 cr0.53%
ASTRAZENAstraZeneca Pharma India Limited Healthcare66,230₹42.2 cr0.46%
INDOCOIndoco Remedies Limited Healthcare16.52 lakh₹34.4 cr0.38%
CONCORDBIOConcord Biotech Limited Healthcare1.12 lakh₹13.9 cr0.15%
Show all 37 stocksShow the first 15

Equity rows as disclosed, Oct 2026. Source: Nippon India Mutual Fund monthly portfolio. Report a wrong number

Large, mid and small caps, % of net assets, last 12 months

AMFI list in force each month
MonthLargeMidSmallNot in AMFI's listAMFI list
Oct 202629.6%40.8%28.7%0.5%Jun 2026
Sep 202629.7%39.0%28.0%0.5%Jun 2026
Aug 202630.6%38.8%28.1%0.4%Jun 2026
Jul 202631.2%38.6%27.6%0.0%Jun 2026
Jun 202639.7%27.1%30.8%0.0%Dec 2025
May 202640.2%27.3%30.4%0.0%Dec 2025
Apr 202641.1%27.8%29.8%0.0%Dec 2025
Mar 202640.1%28.5%30.9%0.0%Dec 2025
Feb 202639.8%28.5%31.4%0.0%Dec 2025
Jan 202638.4%28.3%32.3%0.0%Dec 2025
Dec 202548.0%19.6%28.9%0.8%Jun 2025
Nov 202549.1%20.0%29.6%0.8%Jun 2025
Sources: Nippon India Mutual Fund monthly portfolios; AMFI. How to read

Equity holdings' % of net assets each month, by AMFI's cap list in force that month.

Portfolio turnover, from holdings

equity only · month-end snapshots
Turnover, 12 months17.2%Oct 2025 to Oct 2026 · bought ₹1,462 cr, sold ₹1,538 cr
MonthBoughtSoldTurnover
Oct 2026₹278 cr₹96.8 cr1.1%
Sep 2026₹1.1 cr₹34.5 cr0.0%
Aug 2026₹211 cr₹141 cr1.5%
Jul 2026₹138 cr₹124 cr1.4%
Jun 2026₹116 cr₹146 cr1.3%
May 2026₹155 cr₹222 cr1.9%
Apr 2026₹152 cr₹209 cr1.9%
Mar 2026₹0.00 cr₹27.1 cr0.0%
Feb 2026₹205 cr₹163 cr2.0%
Jan 2026₹114 cr₹32.0 cr0.4%
Dec 2025₹33.3 cr₹242 cr0.4%
Nov 2025₹58.4 cr₹99.7 cr0.7%
Source: Nippon India Mutual Fund monthly portfolios. How to read

The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.

Returns next to the benchmark

What the plan's NAV did over each period, as AMFI publishes it.

as of 13 Nov 2026 · as published by AMFI
PeriodDirect planRegular planBenchmark, as published by AMFI BSE Healthcare TRI
1 year+14.10 %+13.11 %+19.29 %
3 years+18.54 %+17.49 %+22.97 %
5 years+15.24 %+14.22 %+16.71 %
10 years+16.27 %+15.24 %+13.77 %
Since launch+17.57 %+19.87 %+15.11 %

Past performance may not be sustained in future.

Source: AMFI fund performance

As AMFI's fund performance report prints them for "Nippon India Pharma Fund"; this site computes no benchmark figure of its own.

How to read

How it is computed: NAV to NAV

Nippon India Pharma Fund - Direct Plan - Growth Option: these run to the newest NAV stored (16 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 13 Nov 2026, so the two differ by the days in between.

PeriodReturnFromTo
1 year+13.69 % in total 14 Nov 2025 · NAV ₹579.979216 Nov 2026 · NAV ₹659.3613
3 years+18.15 % a year, compounded 16 Nov 2023 · NAV ₹399.597416 Nov 2026 · NAV ₹659.3613
5 years+14.96 % a year, compounded 16 Nov 2021 · NAV ₹328.260716 Nov 2026 · NAV ₹659.3613
Since first NAV+17.55 % a year, compounded 2 Jan 2013 · NAV ₹69.864816 Nov 2026 · NAV ₹659.3613

Source: AMFI NAV files (plan code 118759). How to read Report a wrong number

IDCW (dividend) history

14 declarations · as of 29 Oct 2026 · Source: AMFI
DatePlanOptionA unit
1 Mar 2018Direct PlanIDCW Option₹6
1 Mar 2018Regular PlanIDCW Option₹6
3 Mar 2017Direct PlanIDCW Option₹6.5
3 Mar 2017Regular PlanIDCW Option₹6.5
4 Mar 2016Direct PlanIDCW Option₹7
4 Mar 2016Regular PlanIDCW Option₹7
30 Jan 2015Direct PlanIDCW Option₹7
30 Jan 2015Regular PlanIDCW Option₹7
14 Feb 2014Direct PlanIDCW Option₹4.5
14 Feb 2014Regular PlanIDCW Option₹4.5
11 Jan 2013Regular PlanIDCW Option₹3.5
16 Mar 2012Regular PlanIDCW Option₹1
25 Feb 2011Regular PlanIDCW Option₹2.5
28 Aug 2009Regular PlanIDCW Option₹1.5
Source: AMFI scheme dividends. How to read

IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.

Rolling returns, Nippon India Pharma Fund - Direct Plan - Growth Option

weekly NAVs · Source: AMFI
WindowLowestMedianHighestWindows above zero
1 year in total −14.91 % 11 Jun 2021 to 17 Jun 2022+13.23 % 28 Mar 2024 to 28 Mar 2025+84.98 % 27 Mar 2020 to 1 Apr 2021 77 % of 664 windows ending 10 Jan 2014 to 16 Nov 2026
3 years a year, compounded −1.29 % 23 Oct 2015 to 26 Oct 2018+19.68 % 27 Oct 2017 to 30 Oct 2020+31.66 % 20 Jul 2018 to 23 Jul 2021 99 % of 568 windows ending 8 Jan 2016 to 16 Nov 2026
5 years a year, compounded +1.31 % 27 Mar 2015 to 27 Mar 2020+16.57 % 29 Apr 2016 to 30 Apr 2021+31.71 % 11 Oct 2019 to 11 Oct 2024 100 % of 463 windows ending 5 Jan 2018 to 16 Nov 2026

Past performance may not be sustained in future.

Source: AMFI NAV files. How to read

Every 1-, 3- and 5-year window ending on a week's last NAV, lowest, middle and highest.

Volatility, a year

Standard deviation of weekly NAV changes × √52. 17 Nov 2023 to 16 Nov 2026, 157 weekly changes.

Source: AMFI

13.84 %157 weeks to 16 Nov 2026
Largest fall from a high

High 30 Oct 2015, low 26 May 2017; back at the high 17 Aug 2018.

Weekly NAVs since 4 Jan 2013. Measured on each week's last NAV, so a fall within a week can be deeper than shown.

Source: AMFI

−23.20 %low 26 May 2017

Past performance may not be sustained in future.

Next to its category: Sectoral or thematic

weekly NAVs · Source: AMFI
Rolling windowLower quarterUpper quarterAbove 6 %Above 9 %Above 12 %Above the category average
1 year+0.4 %+38.5 % 63.1 %57.7 %52.1 % 51.5 % of 664 windows
3 years+9.9 %+24.1 % 77.5 %75.5 %73.9 % 54.8 % of 568 windows
5 years+13.5 %+18.8 % 93.3 %86.6 %82.1 % 57.5 % of 463 windows
How this is counted

Same windows as the rolling returns above. A quarter of the windows returned less than the lower quarter, and a quarter more than the upper. "Above" columns give the share of windows. The category average is the average for windows ending the same week.

Market phases

PhaseDatesThis schemeCategory average
Slowdown, 2015–1627 Feb 2015 to 26 Feb 2016 in total+4.0 %−15.9 % 48 schemes
Rise, 2016–1826 Feb 2016 to 31 Aug 2018 a year, compounded+9.6 %+23.6 % 55 schemes
To the COVID low31 Aug 2018 to 27 Mar 2020 a year, compounded−8.8 %−17.9 % 58 schemes
Rise from the COVID low27 Mar 2020 to 27 Sep 2024 a year, compounded+35.7 %+37.3 % 70 schemes
Foreign selling, 2024–2527 Sep 2024 to 28 Feb 2025 in total−13.5 %−19.0 % 150 schemes
Since March 202528 Feb 2025 to 16 Nov 2026 a year, compounded+17.3 %+15.2 % 168 schemes

The phases are the site's own split of the market since 2015, measured from month end to month end.

From each quarter end to the newest NAV

FromDatesThis schemeCategory average
From Jun 202625 Jun 2026 to 16 Nov 2026 in total+6.6 %+4.1 % 199 schemes
From Mar 202627 Mar 2026 to 16 Nov 2026 in total+18.7 %+17.5 % 199 schemes
From Dec 202526 Dec 2025 to 16 Nov 2026 in total+15.8 %+6.1 % 192 schemes
From Sep 202526 Sep 2025 to 16 Nov 2026 a year, compounded+16.2 %+8.3 % 185 schemes
From Jun 202527 Jun 2025 to 16 Nov 2026 a year, compounded+10.1 %+5.5 % 176 schemes
From Mar 202528 Mar 2025 to 16 Nov 2026 a year, compounded+13.7 %+11.5 % 172 schemes
From Dec 202427 Dec 2024 to 16 Nov 2026 a year, compounded+7.4 %+5.4 % 162 schemes
From Sep 202427 Sep 2024 to 16 Nov 2026 a year, compounded+6.2 %+1.3 % 150 schemes
From Jun 202428 Jun 2024 to 16 Nov 2026 a year, compounded+13.0 %+5.2 % 139 schemes
From Mar 202428 Mar 2024 to 16 Nov 2026 a year, compounded+13.5 %+9.7 % 133 schemes
From Dec 202329 Dec 2023 to 16 Nov 2026 a year, compounded+15.8 %+11.4 % 127 schemes
From Sep 202329 Sep 2023 to 16 Nov 2026 a year, compounded+18.6 %+14.4 % 118 schemes
Spread of falling weeks, a year

Root mean square of the weekly falls × √52 (rising weeks count as zero).

8.8 %17 Nov 2023 to 16 Nov 2026
Up capture

Its average change in the 93 weeks the category average rose, as a share of the category's.

86.1 %93 rising weeks
Down capture

The same for the 64 weeks the category average fell.

71.4 %64 falling weeks

Past performance may not be sustained in future.

Source: AMFI NAV files.

Category average = the plain average for the other schemes in the same AMFI category with the same figure (direct growth plans, each week's last NAV). It is not an index, and the scheme's place among them is not shown. Peers are today's schemes in today's category, so a scheme that has closed is not in the average, and SEBI re-sorted the categories in 2018.

52-week high NAV

Highest and lowest of 247 daily NAVs, 17 Nov 2025 to 16 Nov 2026, Nippon India Pharma Fund - Direct Plan - Growth Option.

Source: AMFI

₹663.121811 Nov 2026
52-week low NAV₹539.270729 Jan 2026

Calendar-year returns, Nippon India Pharma Fund - Direct Plan - Growth Option

NAV to NAV · Source: AMFI
YearReturnFromTo
2025−2.46 % 31 Dec 2024 · NAV ₹584.191231 Dec 2025 · NAV ₹569.8166
2024+35.26 % 29 Dec 2023 · NAV ₹431.911431 Dec 2024 · NAV ₹584.1912
2023+40.36 % 30 Dec 2022 · NAV ₹307.727529 Dec 2023 · NAV ₹431.9114
2022−9.06 % 31 Dec 2021 · NAV ₹338.397630 Dec 2022 · NAV ₹307.7275
2021+25.12 % 31 Dec 2020 · NAV ₹270.459431 Dec 2021 · NAV ₹338.3976
2020+67.92 % 31 Dec 2019 · NAV ₹161.062931 Dec 2020 · NAV ₹270.4594
2019+2.51 % 31 Dec 2018 · NAV ₹157.123331 Dec 2019 · NAV ₹161.0629
2018+4.56 % 29 Dec 2017 · NAV ₹150.277331 Dec 2018 · NAV ₹157.1233
2017+8.57 % 30 Dec 2016 · NAV ₹138.419229 Dec 2017 · NAV ₹150.2773
2016−9.74 % 31 Dec 2015 · NAV ₹153.362130 Dec 2016 · NAV ₹138.4192

Past performance may not be sustained in future.

Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read

Monthly SIP of ₹10,000, Nippon India Pharma Fund - Direct Plan - Growth Option

XIRR · Source: AMFI
PeriodInstalmentsPaid inValueXIRR, a year
1 year 1 Dec 2025 to 2 Nov 202612 ₹1,20,000₹1,33,002 16 Nov 2026 · NAV ₹659.3613+22.46 %

Past performance may not be sustained in future.

Source: AMFI NAV files. How to read

₹10,000 on the first NAV of each month, valued at the newest NAV; no stamp duty, exit load or tax taken off.

Embed this card

Card for this scheme: facts with source and date

Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.

Portfolios most like this one, Oct 2026

same category, other fund houses
Most alike and most unique funds →

Overlap is the sum, over stocks both hold, of the smaller of the two weights. A measured likeness, not a suggestion to switch.

Portfolio overlap, side by side

common stocks with each fund's weight

From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.

Questions about Nippon India Pharma Fund

from the figures on this page

What are the top holdings of Nippon India Pharma Fund?

At Oct 2026 end, Nippon India Pharma Fund held 37 stocks (99.6% of the fund in equity). Largest: Sun Pharmaceutical Industries 11.55%, Divi's Laboratories 6.73%, Cipla 6.21%, Lupin 6.16%, Dr. Reddy's Laboratories 6.13%; the top 10 make up 57.2%. Funds holding Sun Pharmaceutical Industries · Funds holding Divi's Laboratories · Funds holding Cipla

What portfolio changes did Nippon India Pharma Fund make in Oct 2026?

Compared with Sep 2026, by share count: 1 new, 5 added, 3 trimmed, 0 exited. Largest by value: Natco Pharma (new), Dr. Reddy's Laboratories (added), Max Healthcare Institute (added), Fortis Healthcare (added).

Who manages Nippon India Pharma Fund?

AMFI's scheme summary document names Sailesh Raj Bhan for Nippon India Pharma Fund (Nippon India Mutual Fund). Sailesh Raj Bhan, fund manager portfolio

All schemes of Nippon India Mutual Fund →

Mutual fund investments are subject to market risks; read all scheme related documents carefully.